We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Inthushaa
Indrakumar
i.indrakumar@qmul.ac.uk
Prof
Costantino
Pitzalis
c.pitzalis@qmul.ac.uk
Alessia
Baseggio Conrado
a.baseggioconrado@qmul.ac.uk
Alessia
Baseggio Conrado
a.baseggioconrado@qmul.ac.uk
Inflammatory polyarthropathiesPapulosquamous disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Currently upwards of 400 patients suffering from inflammatory arthritis (predominantly Rheumatoid and Psoriatic
arthritis) have been recruited primarily to synovial biopsy based studies led by the Centre for Experimental Medicine
and Rheumatology at Barts Health NHS Trust.
Patients within the cohort (including Rheumatoid Athritis, Psoriatic Athritis) have been recruited at varying stages of
disease progression including at disease onset: PEAC - Pathobiology of Early Arthritis cohort, IRMA study; following
failure to respond to traditional disease modifying anti-rheumatic drugs (DMARDs): THERAPIST study, STRAP trial;
and following the failure to first line biologic therapy: R4-RA pilot study and R4-RA trial.
In Psoriatic Arthritis a similar study design recruits patients who have failed standard non-biologic disease-modifying
drugs; PSABRE study.
Data collected as part of the above studies include but are not be limited to:
Disease activity Scores: DAS28, ACR20, CDAI, SDAI, PASDAS
Quality of life indicators: SF36, HAQ, EQ5D, WLQ, FACIT fatique questionnaire, PsAQoL, PASI-75, DLQI, Global health
scores
Blood laboratory results including but not limited to: Haematology, Immunology, biochemistry, microbiology
Imaging (ultrasound and x-ray) of all modalities: raw images and reports
Healthcare utilisation: appointments and admissions for treatments (planned and unplanned)
Data collected in other ethically approved clinical studies would be collated for patients who are also enrolled in
CRMSIA. This would include laboratory and bedside data related to the patients disease.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Not affected by above condition
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Alessia
Baseggio Conrado
a.baseggioconrado@qmul.ac.uk
Prof
Costantino
Pitzalis
c.pitzalis@qmul.ac.uk
Inthushaa
Indrakumar
i.indrakumar@qmul.ac.uk
Alessia
Baseggio Conrado
a.baseggioconrado@qmul.ac.uk
The study is sponsored by Queen Mary University of London and funded by Medical Research Council (MRC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 37570
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
